Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 January 2024Website:
http://www.arrivent.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 1 min agoDividend
Analysts recommendations
Institutional Ownership
AVBP Latest News
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session
ArriVent BioPharma, Inc., a company focused on advancing innovative biopharmaceutical therapeutics globally, has appointed John Hohneker, M.D. to its Board of Directors. Dr. Hohneker, who has more than three decades of experience in biopharmaceutical leadership and drug development, currently sits on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., as well as private companies Sonata Therapeutics and Trishula Therapeutics.
ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding Greater China, to furmonertinib, a highly targeted drug used to treat non-small-cell lung cancer.
What type of business is ArriVent BioPharma Common Stock?
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
What sector is ArriVent BioPharma Common Stock in?
ArriVent BioPharma Common Stock is in the Healthcare sector
What industry is ArriVent BioPharma Common Stock in?
ArriVent BioPharma Common Stock is in the Biotechnology industry
What country is ArriVent BioPharma Common Stock from?
ArriVent BioPharma Common Stock is headquartered in United States
When did ArriVent BioPharma Common Stock go public?
ArriVent BioPharma Common Stock initial public offering (IPO) was on 26 January 2024
What is ArriVent BioPharma Common Stock website?
https://www.arrivent.com
Is ArriVent BioPharma Common Stock in the S&P 500?
No, ArriVent BioPharma Common Stock is not included in the S&P 500 index
Is ArriVent BioPharma Common Stock in the NASDAQ 100?
No, ArriVent BioPharma Common Stock is not included in the NASDAQ 100 index
Is ArriVent BioPharma Common Stock in the Dow Jones?
No, ArriVent BioPharma Common Stock is not included in the Dow Jones index
When was ArriVent BioPharma Common Stock the previous earnings report?
No data
When does ArriVent BioPharma Common Stock earnings report?
The next expected earnings date for ArriVent BioPharma Common Stock is 28 February 2025